The MELAcare Study: A New Method for Surveillance of Melanoma Patients
About this study
The aim of this study is to evaluate a new method of follow-up for patients with low and intermediate risk (stages IA-IIA) melanoma. The investigators will compare different tools for patient support and education combined with clinician supported skin self-examination (SSE) to the current standard-of-care. The hypothesis is that meta-cognitive strategies and clinician supported SSE can lower fear of cancer recurrence (FCR) and promote effective SSE on a regular basis without compromising the detection of new primary melanomas and/or metastases.
- Condition
- Cutaneous Melanoma
- Tested
- The MelaCare intervention
- Sponsor
- Herlev and Gentofte Hospital
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 18 years
- Study condition: Cutaneous Melanoma
- Ability to read and understand Danish language
- Willing and able to give written informed consent
- Surgical treatment of a clinical stage IA-IIA melanoma within 3 months of inclusion
Exclusion 6
- Advanced melanoma, clinical stages IIB, IIC, III, or IV
- Patients with high risk of a new primary melanoma (dysplastic nevus syndrome, or family history of melanoma)
- History of melanoma skin cancer prior to the index diagnosis
- Previous cancer, excluding non-melanoma skin cancer
- Comorbidity that makes skin self-examination impossible (e.g. physical or mental disabilities, dementia or decreased cognitive function)
- non-detection of sentinel node in IB and IIA patients
Where
1 site, 1 recruiting
Herlev and Gentofte Hospital
Copenhagen, Denmark
Contact
-
Sara M Hansen, MD
+4538681296 sara.moelgaard.hansen@regionh.dk
-
Lisbet R Hölmich, Professor
+4538681243 lisbet.rosenkrantz.hoelmich@regionh.dk
Potential match only. Final eligibility is determined by the study team.